vs
CSX Corporation（CSX）与汉瑞祥（HSIC）财务数据对比。点击上方公司名可切换其他公司
CSX Corporation的季度营收约是汉瑞祥的1.0倍（$3.5B vs $3.4B），CSX Corporation净利率更高（23.2% vs 2.9%，领先20.2%），汉瑞祥同比增速更快（7.7% vs 1.7%），CSX Corporation自由现金流更多（$793.0M vs $338.0M），过去两年汉瑞祥的营收复合增速更高（4.1% vs -3.0%）
CSX运输是美国一级货运铁路企业，业务覆盖美国东部区域及加拿大安大略省、魁北克省，运营铁路总里程约3.4万公里，隶属于总部位于佛罗里达州杰克逊维尔市的财富500强企业CSX Corporation，是其旗下核心子公司。
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
CSX vs HSIC — 直观对比
营收规模更大
CSX
是对方的1.0倍
$3.4B
营收增速更快
HSIC
高出6.0%
1.7%
净利率更高
CSX
高出20.2%
2.9%
自由现金流更多
CSX
多$455.0M
$338.0M
两年增速更快
HSIC
近两年复合增速
-3.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $3.4B |
| 净利润 | $807.0M | $101.0M |
| 毛利率 | — | 30.9% |
| 营业利润率 | 29.9% | 4.7% |
| 净利率 | 23.2% | 2.9% |
| 营收同比 | 1.7% | 7.7% |
| 净利润同比 | 401.2% | 7.4% |
| 每股收益（稀释后） | — | $0.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSXHSIC
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $3.4B | ||
| Q3 25 | $3.6B | $3.3B | ||
| Q2 25 | $3.6B | $3.2B | ||
| Q1 25 | $3.4B | $3.2B | ||
| Q4 24 | $3.5B | $3.2B | ||
| Q3 24 | $3.6B | $3.2B | ||
| Q2 24 | $3.7B | $3.1B |
净利润CSXHSIC
| Q1 26 | $807.0M | — | ||
| Q4 25 | $720.0M | $101.0M | ||
| Q3 25 | $694.0M | $101.0M | ||
| Q2 25 | $829.0M | $86.0M | ||
| Q1 25 | $646.0M | $110.0M | ||
| Q4 24 | $720.0M | $94.0M | ||
| Q3 24 | $894.0M | $99.0M | ||
| Q2 24 | $963.0M | $104.0M |
毛利率CSXHSIC
| Q1 26 | — | — | ||
| Q4 25 | — | 30.9% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | 31.4% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | — | 31.1% | ||
| Q3 24 | — | 31.3% | ||
| Q2 24 | — | 32.5% |
营业利润率CSXHSIC
| Q1 26 | 29.9% | — | ||
| Q4 25 | 31.6% | 4.7% | ||
| Q3 25 | 30.3% | 4.9% | ||
| Q2 25 | 35.9% | 4.7% | ||
| Q1 25 | 30.4% | 5.5% | ||
| Q4 24 | 30.8% | 4.9% | ||
| Q3 24 | 37.4% | 4.9% | ||
| Q2 24 | 39.1% | 5.1% |
净利率CSXHSIC
| Q1 26 | 23.2% | — | ||
| Q4 25 | 20.5% | 2.9% | ||
| Q3 25 | 19.3% | 3.0% | ||
| Q2 25 | 23.2% | 2.7% | ||
| Q1 25 | 18.9% | 3.5% | ||
| Q4 24 | 20.3% | 2.9% | ||
| Q3 24 | 24.7% | 3.1% | ||
| Q2 24 | 26.0% | 3.3% |
每股收益（稀释后）CSXHSIC
| Q1 26 | — | — | ||
| Q4 25 | $0.39 | $0.85 | ||
| Q3 25 | $0.37 | $0.84 | ||
| Q2 25 | $0.44 | $0.70 | ||
| Q1 25 | $0.34 | $0.88 | ||
| Q4 24 | $0.38 | $0.75 | ||
| Q3 24 | $0.46 | $0.78 | ||
| Q2 24 | $0.49 | $0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $156.0M |
| 总债务越低越好 | $18.9B | $2.3B |
| 股东权益账面价值 | $13.6B | $3.2B |
| 总资产 | $44.2B | $11.2B |
| 负债/权益比越低杠杆越低 | 1.39× | 0.71× |
8季度趋势，按日历期对齐
现金及短期投资CSXHSIC
| Q1 26 | $1.1B | — | ||
| Q4 25 | $5.0M | $156.0M | ||
| Q3 25 | $6.0M | $136.0M | ||
| Q2 25 | $6.0M | $145.0M | ||
| Q1 25 | $8.0M | $127.0M | ||
| Q4 24 | $72.0M | $122.0M | ||
| Q3 24 | $12.0M | $126.0M | ||
| Q2 24 | $4.0M | $138.0M |
总债务CSXHSIC
| Q1 26 | $18.9B | — | ||
| Q4 25 | $18.2B | $2.3B | ||
| Q3 25 | $18.6B | $2.2B | ||
| Q2 25 | $18.6B | $2.1B | ||
| Q1 25 | $18.5B | $2.0B | ||
| Q4 24 | $17.9B | $1.8B | ||
| Q3 24 | $18.5B | $1.9B | ||
| Q2 24 | $18.0B | $1.9B |
股东权益CSXHSIC
| Q1 26 | $13.6B | — | ||
| Q4 25 | $13.2B | $3.2B | ||
| Q3 25 | $12.8B | $3.4B | ||
| Q2 25 | $12.4B | $3.4B | ||
| Q1 25 | $12.2B | $3.3B | ||
| Q4 24 | $12.5B | $3.4B | ||
| Q3 24 | $12.9B | $3.5B | ||
| Q2 24 | $12.6B | $3.5B |
总资产CSXHSIC
| Q1 26 | $44.2B | — | ||
| Q4 25 | $43.7B | $11.2B | ||
| Q3 25 | $43.3B | $11.1B | ||
| Q2 25 | $42.9B | $10.9B | ||
| Q1 25 | $43.2B | $10.5B | ||
| Q4 24 | $42.8B | $10.2B | ||
| Q3 24 | $43.1B | $10.6B | ||
| Q2 24 | $42.4B | $10.3B |
负债/权益比CSXHSIC
| Q1 26 | 1.39× | — | ||
| Q4 25 | 1.38× | 0.71× | ||
| Q3 25 | 1.45× | 0.64× | ||
| Q2 25 | 1.50× | 0.61× | ||
| Q1 25 | 1.52× | 0.59× | ||
| Q4 24 | 1.43× | 0.54× | ||
| Q3 24 | 1.43× | 0.54× | ||
| Q2 24 | 1.42× | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $381.0M |
| 自由现金流经营现金流 - 资本支出 | $793.0M | $338.0M |
| 自由现金流率自由现金流/营收 | 22.8% | 9.8% |
| 资本支出强度资本支出/营收 | — | 1.3% |
| 现金转化率经营现金流/净利润 | 1.58× | 3.77× |
| 过去12个月自由现金流最近4个季度 | $2.0B | $573.0M |
8季度趋势，按日历期对齐
经营现金流CSXHSIC
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $381.0M | ||
| Q3 25 | $1.3B | $174.0M | ||
| Q2 25 | $635.0M | $120.0M | ||
| Q1 25 | $1.3B | $37.0M | ||
| Q4 24 | $1.4B | $204.0M | ||
| Q3 24 | $1.7B | $151.0M | ||
| Q2 24 | $1.1B | $296.0M |
自由现金流CSXHSIC
| Q1 26 | $793.0M | — | ||
| Q4 25 | $709.0M | $338.0M | ||
| Q3 25 | $607.0M | $141.0M | ||
| Q2 25 | $-141.0M | $88.0M | ||
| Q1 25 | $536.0M | $6.0M | ||
| Q4 24 | $550.0M | $168.0M | ||
| Q3 24 | $1.1B | $117.0M | ||
| Q2 24 | $547.0M | $259.0M |
自由现金流率CSXHSIC
| Q1 26 | 22.8% | — | ||
| Q4 25 | 20.2% | 9.8% | ||
| Q3 25 | 16.9% | 4.2% | ||
| Q2 25 | -3.9% | 2.7% | ||
| Q1 25 | 15.7% | 0.2% | ||
| Q4 24 | 15.5% | 5.3% | ||
| Q3 24 | 29.3% | 3.7% | ||
| Q2 24 | 14.8% | 8.3% |
资本支出强度CSXHSIC
| Q1 26 | — | — | ||
| Q4 25 | 19.3% | 1.3% | ||
| Q3 25 | 20.4% | 1.0% | ||
| Q2 25 | 21.7% | 1.0% | ||
| Q1 25 | 21.0% | 1.0% | ||
| Q4 24 | 23.7% | 1.1% | ||
| Q3 24 | 17.3% | 1.1% | ||
| Q2 24 | 14.6% | 1.2% |
现金转化率CSXHSIC
| Q1 26 | 1.58× | — | ||
| Q4 25 | 1.93× | 3.77× | ||
| Q3 25 | 1.93× | 1.72× | ||
| Q2 25 | 0.77× | 1.40× | ||
| Q1 25 | 1.94× | 0.34× | ||
| Q4 24 | 1.93× | 2.17× | ||
| Q3 24 | 1.89× | 1.53× | ||
| Q2 24 | 1.13× | 2.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSX
暂无分部数据
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
